University of Hertfordshire

ANNUAL PROGRESS REPORTS AND DSURS
(SPONSORED/CO-SPONSORED)

Clinical Trials Support Network (CTSN)

Standard Operating Procedure for the Generation and Submission of Development Safety Update Reports and Annual Progress Reports for UH Sponsored/Co-Sponsored Clinical Trials

<table>
<thead>
<tr>
<th>SOP Number : gSOP-16-01</th>
<th>Effective Date: 26th April 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Version Number: v1.0</td>
<td>Review Date: 3 years (or as required)</td>
</tr>
</tbody>
</table>

1.0 BACKGROUND

This is a University of Hertfordshire standard operating procedure. University of Hertfordshire (UH) acknowledges West Hertfordshire Hospitals NHS Trust (WHHT) Research & Development (R&D) which has allowed UH to use the SOPs developed by WHHT where possible, modified for local implementation.

This document sets out the procedures to be followed by all UH staff who are involved in the preparation, review or dissemination of progress reports for ethics committees and regulatory bodies (including but not limited to the MHRA) for UH sponsored/co-sponsored studies. These progress reports include annual reports and Development Safety Update Reports (DSURs).

It is a requirement of ethical and regulatory approval that annual reports are submitted.

It aims to provide clear guidance on the timing and content of DSURs to ensure compliance with the regulatory bodies.

2.0 PURPOSE

This document defines the research procedures for the preparation and submission of periodic safety reporting and annual reports including DSURs for research studies and clinical Trials sponsored/co-sponsored by UH.

The document clarifies the requirements for safety reporting to the regulatory authorities so as to aid compliance with Good Clinical Practice (GCP).

The document aims to provide clear guidance on when and how to prepare annual reports and DSURs so as to comply with the regulatory requirements. The DSUR is a standard document for the periodic reporting on drugs under development (included marketed drugs that are under further study).
The objective of the DSUR is to provide a comprehensive review and evaluation of the pertinent safety information collected during the reporting period. This will:

- Examine whether the information obtained by the sponsor during the reporting period is in accordance with previous knowledge of the drug’s safety
- Describe any new safety issues
- Summarise the current understanding and management of the known and potential risks
- Provide and update on the status of the clinical investigation/development programme and study results

3.0 APPLICABLE TO

The submission of safety reports is delegated by the Sponsor to the Chief Investigator (CI) or Delegated Individual (DI) and their study team involved in the managements of UH sponsored/co-sponsored clinical trials.

This applies to, but is not limited to, all staff involved in clinical research sponsored/co-sponsored by UH, including: Chief Investigators, Principal Investigators, Research Fellows, Consultants, Statisticians, Clinical Trial Pharmacists, Research Managers, Research Nurses, Clinical Trial Practitioners, Allied Health Professionals, Trial Coordinators, Clinical Studies Officers, Data Managers and Students.

4.0 RESPONSIBILITIES

The trial sponsor is responsible for the preparation, content and submission of the annual reports/DSUR although they may delegate the actual task to a competent member of the study team. This delegation must be on the Sponsor/CI delegation log.

5.0 PROCEDURE

For CTIMPS – Preparation of the DSUR:

5.1 Annual Reporting period and Development International Birth Date (DIBD)

5.1.1 The “Development International Birth Date” (DIBD) is used to determine the start of the annual period for the DSUR. This date is the sponsor’s first authorisation to conduct a clinical trial in any country worldwide. The start of the annual period for the DSUR is the month and date of the DIBD.

5.1.2 The start of the Annual Reporting Period will be the month and date of the DIBD. For clinical trials that commenced before 1 May 2004, the reporting period starts with the issue date of the Clinical trial exemption (CTX) letter or first Differential diagnosis (DDX) exemption letter by the MHRA.

5.1.3. Where the same Investigational Medicinal Product (IMP) is used in different trials, the data will be provided by indication.

5.2 Data-Lock date
5.2.1 The data lock point of the DSUR should be the last day of the one-year reporting period. For administrative convenience, if desired by the sponsor, the data lock point of the DSUR can be designated as the last day of the month prior to the month of the DIBD.

5.2.2 The DSUR should be submitted to all concerned regulatory authorities no later than 60 calendar days after the DSUR data lock point.

**5.3 Preparation of the DSUR and co-ordinated responsibilities**

5.3.1 The Sponsor of a clinical trial is considered responsible for the preparation, content and submission of a DSUR. The sponsor can delegate the preparation of the DSUR to a third party (e.g. a contract research organisation).

5.3.2 The CI/DI will complete their relevant sections and return to the Sponsor representative. The delegated member of the research team will also send all appendices to the Sponsor representative.

5.3.3 The Sponsor representative will compile all the relevant information then forward the DSUR to the MHRA and the REC with a final copy sent to the research teams.

5.3.4 The final documents are to be stored in the Trial Master File.

**5.4 Completion of the DSUR**

5.4.1 The CI will receive a reminder email from the Sponsor representative on the anniversary of the trial’s Clinical Trials Authorisation.


5.4.3 The Sponsor representative will be the point of contact going forward for all questions/queries related to the completion and submission of the DSUR.

5.4.4 The DSUR contains sections for completion by the CI/trial team and sections for completion by the Sponsor.

5.4.5 The CI/DI should complete those sections marked for their attention in the template.

5.4.6 The Sponsor representative will then complete those sections that are for the Sponsor’s attention, check that the instructions in the template have been appropriately followed and the current approved Reference Safety Information (RSI) has been used.

5.4.7 The draft DSUR must be provided to the Sponsor representative 2 weeks prior to the submission deadline.

5.4.8 Any necessary alterations agreed are made by the CI or the Sponsor representative in the relevant sections as appropriate.

5.4.9 The final DSUR will then be reviewed and signed by the Sponsor’s representative and the CI.
5.4.10 The Sponsor representative will submit the DSUR and the supporting documents i.e. cover letter, approved RIS, publications and abstracts (as applicable) via CESP, the online portal for MHRA submissions.

5.4.11 The Sponsor representative will provide the CI/trial team with a copy of the full DSUR submission for submission to the REC and for filing in the TMF.

5.4.12 It is the responsibility of the CI to provide the DSUR and accompanying documents (including the Safety Report Form) to the REC which gave favourable opinion for the trial, via email.

5.4.13 The Sponsor representative will file a copy of the CESP upload email as confirmation that the DSUR has been submitted to the MHRA.

5.4.14 When received, a copy will be filed in the Sponsor file and the original confirmation forwarded to the trial team for filing in the TMF.

5.5 DSURs for combination therapy

5.5.1 DSURs are IMP-specific and it is the sponsor’s responsibility to ensure a single DSUR is submitted for individual IMPs.

5.5.2 In cases of multi-drug therapy trials, where it is not possible to submit DSURs for individual IMPs, the Sponsor representative in conjunction with the P.I or C.I, will arrange to prepare a DSUR for the multi-drug therapy.

5.6 Submission of the final DSUR

Ensure that all the original reports are signed and dated appropriately.

<table>
<thead>
<tr>
<th>DSUR Submission</th>
<th>Annual Progress Report Submission</th>
</tr>
</thead>
<tbody>
<tr>
<td>Send DSUR to the MHRA via CESP (refer to the MHRA website for current requirements)</td>
<td>Send completed and signed Annual Progress Report (APR) form to the REC via email</td>
</tr>
<tr>
<td>Include covering letter and all appendices</td>
<td>No covering letter</td>
</tr>
<tr>
<td>Send a copy of the DSUR to the REC on disk or via email accompanied by the REC CTIMP safety report form</td>
<td></td>
</tr>
</tbody>
</table>

For Sponsored trials make two copies of all the signed documents, one set for filing in the TMF, send the second set to the UH Research Office for inclusion in the Sponsor files. For co-sponsored trials a third set should be sent to the Trust R&D office for their records.

For all Clinical Trials:

5.7 Annual Progress Reports Submitted to the REC Only
It is a requirement for continued favourable opinion from the REC that an APR be submitted annually, i.e., within 30 days of the anniversary date of favourable opinion for the study which was received from the REC.

The APR template (for CTIMPs / for non-CTIMPs) published on the HRA website must be used:

- The CI will receive a reminder email from the Sponsor Representative on the anniversary of the Favourable Opinion from the REC for their trial
- If any extension to the duration of the trial is required, this must be included in the APR as notification of the extension to the REC
- A final signed copy of the APR and submission email must be submitted to the Sponsor representative for review and inclusion in the Sponsor file and to the UH Advisory Group on Research Governance for Clinical Studies.

The trial team should notify participating sites of any change in the duration of the trial as stated in the APR as soon as possible by normally 10 working days after submission.

The trial team should request participating sites to acknowledge the receipt of the APR form. A copy of the APR and acknowledgement of receipt from the REC should be filed in the Sponsor file and in the Trial Master File (TMF).

6.0 RELATED DOCUMENTS

- gSOP-02- Adverse Event reporting (Sponsored/co-sponsored)
- The Development Safety Update Report (DSUR) Guidance – ICH E2F
- For information on submission to the MHRA please refer to the MHRA website
- For information on submission to the HRA (REC) please refer to the HRA website

7.0 APPENDICES

- Appendix 1 – Definitions
- Appendix 2 – Example DSUR

8.0 VERSION HISTORY

<table>
<thead>
<tr>
<th>Revision Chronology:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Version Number</td>
</tr>
<tr>
<td>---</td>
</tr>
</tbody>
</table>

9.0 AUTHORSHIP & APPROVAL

Author

Signature

Date

Page 5 of 16

This document is uncontrolled if printed. Current electronic version of this document should be accessed via the university website.
10. AGREEMENT (MOVE ON TO SEPARATE SHEET BEFORE PRINTING)

Please detach and retain within your training files

I have read and understood the contents and requirements of this SOP (ref gSOP-16-01) and accept to follow University policies implementing it.

Recipient

Signature: …………………………………………………Date: …………………..

Name & Position: ……………………………………………………………………

Please retain copy of the signed form for your reference in your training file

Appendix 1: Definitions

Chief Investigator (CI)
A Registered Physician, Dentist, Pharmacist or Registered Nurse who has overall responsibility for the conduct of the trial.
Clinical Trial
A research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or control) to evaluate the effects of those interventions on health outcomes.

Clinical Trial of Investigational Medicinal Product (CTIMP)
A study that looks at the safety or efficacy of a medicine/food stuff/placebo in humans as defined by the Medicines for Human Use Regulations (2004).

Data Lock Point
This should be the last day of the one year reporting period and the DSUR should be submitted to the MHRA and the REC no later than 60 days after the data lock date.

Delegated Individual (DI)
An individual delegated by the PI to carry out their task(s).

Good Clinical Practice (GCP)
As defined in the Regulations.

International Conference on Harmonisation (ICH)
The ICH produced a series of guidelines in 1996, E6 being the guideline on Good Clinical Practice, otherwise known as (ICH-GCP).

Investigational Medicinal Products (IMP)
A pharmaceutical form of an active substance or placebo being tested, or used as a reference in a clinical trial. This includes a medicinal product which has a marketing authorisation but is, for the purposes of the trial -

(a) used or assembled (formulated or packaged) in a way different from the form of the product authorised under the authorisation,

(b) used for an indication not included in the summary of product characteristics under the authorisation for that product, or

(c) used to gain further information about the form of that product as authorised under the authorisation

Sponsor’s Representative
The Director / Assistant Director of R&D will appoint an appropriate staff member to act as the Sponsor’s Representative.

The Medicines & Healthcare products Regulatory Agency (MHRA)
UK Competent Authority responsible for regulation of clinical trials.

The Regulations
Trial Master File
The Trial Master File (TMF) will be held at the principal site by the sponsor, Chief Investigator or at the co-ordinating Centre. The TMF should contain all essential documents defined as documents which individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced. A Trial Master File should be set up at the beginning of a trial and maintained up-to-date throughout the trial until trial conclusion.

For trials currently running, it is recommended that Section 8 of the ICH-GCP Guideline is followed as guidance in order to meet statutory requirements. However, some of the documents listed may not be available or applicable in many non-commercial trials. The appropriate documentation will vary according to the trial and sponsor requirements.
Appendix 2 - Example DSUR

<table>
<thead>
<tr>
<th>Development Safety Update Report</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Report Number:</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Trial Title:</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Reporting Period:</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Name of IMP</strong></td>
</tr>
<tr>
<td><strong>Sponsor</strong></td>
</tr>
<tr>
<td><strong>Chief Investigator</strong></td>
</tr>
<tr>
<td><strong>Sponsor Address</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Chief Investigator Address</strong></td>
</tr>
<tr>
<td><strong>Date</strong></td>
</tr>
</tbody>
</table>

This report contains confidential information and should not be shared or distributed without the approval of the sponsor.
Executive Summary

Table of Contents

1. Introduction
2. Worldwide Marketing Approval Status
3. Actions Taken in the Reporting Period for Safety Reasons
4. Changes to Reference Safety Information
5. Inventory of Clinical Trials Ongoing and Completed during the Reporting Period
6. Estimated Cumulative Exposure
   6.1 Cumulative Subject Exposure in the Development Programme
   6.2 Patient Exposure from Marketing Experience
7. Data in Line Listings and Summary Tabulations
   7.1 Reference Information
   7.2 Line Listings of Serious Adverse Reactions during the Reporting Period
   7.3 Cumulative Summary Tabulations of Serious Adverse Events
8. Significant Findings from Clinical Trials during the Reporting Period
   8.1 Completed Clinical Trials
   8.2 Ongoing Clinical Trials
   8.3 Long-term Follow-up
   8.4 Other Therapeutic Use of Investigational Drug
   8.5 New Safety Data Related to Combination Therapies
9. Safety Findings from Non-interventional Studies
10. Other Clinical Trial/Study Safety Information
11. Safety Findings from Marketing Experience
12. Non-clinical Data
13. Literature
14. Other DSURs
15. Lack of Efficacy
16. Region-Specific Information
17. Late-Breaking Information
18. Overall Safety Assessment
   18.1. Evaluation of the Risks
   18.2. Benefit-risk Considerations
19. Summary of Important Risks
20. Conclusions

Appendices to the DSUR

1. Introduction

2. Worldwide Marketing Approval Status
3. Actions Taken in the Reporting Period for Safety Reasons

| 4. Changes to Reference Safety Information |

| 5. Inventory of Clinical Trials Ongoing and Completed During the Reporting Period |

| 6. Estimated Cumulative Exposure |

| 6.1 Cumulative Subject Exposure in the Development Programme: |

| 6.2 Patient Exposure from Marketing Experience |
7. Data in Line Listings and Summary Tabulations

7.1 Reference Information

7.2 Line Listings of Serious Adverse Reactions during the Reporting Period

7.3 Cumulative Summary Tabulations of Serious Adverse Events

8. Significant Findings from Clinical Trials during the Reporting Period

8.1 Completed Clinical Trials

8.2 Ongoing Clinical Trials

8.3 Long-term Follow-up

8.4 Other Therapeutic Use of Investigational Drug
8.5 New Safety Data Related to Combination Therapies

9. Safety Findings from Non-interventional Studies

10. Other Clinical Trial/Study Safety Information

11. Safety Findings from Marketing Experience

12. Non-clinical Data
13. Literature

| 14. Other DSURs |

| 15. Lack of Efficacy |

| 16. Region-Specific Information |
17. Late Breaking Information

18. Overall Safety Assessment

18.1 Evaluation of the Risks

18.2 Benefit-risk Considerations

19. Summary of Important Risks

20. Conclusions